ArticleCancer medicine2026
Core Epithelial-to-Mesenchymal Transition Gene Signature Predicts Metastasis and Poor Survival in Synovial Sarcoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Core Epithelial-to-Mesenchymal Transition Gene Signature Predicts Metastasis and Poor Survival in Synovial Sarcoma.Cancer medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundSynovial sarcoma (SS) is a rare soft tissue malignancy comprising 5%-10% of all sarcomas, typically affecting young adults. It is characterized by a pathognomonic SS18-SSX gene fusion, with variable histologic subtypes demonstrating epithelial and mesenchymal features. This study investigates the association between epithelial-to-mesenchymal transition (EMT) gene expression and metastatic potential in SS.
methodsA retrospective, single-institution analysis was conducted using primary tumor specimens from 21 treatment-naïve SS patients. RNA sequencing was performed on formalin-fixed paraffin-embedded (FFPE) tissue to assess gene expression profiles. EMT scores were calculated using three independent methods: Hallmark EMT gene set from GSEA, the 76-gene EMT signature (76GS), and Kolmogorov-Smirnov (KS) testing. Patients were categorized into metastatic and nonmetastatic cohorts, and phenotype-specific survival analyses were conducted.
resultsTumors from patients who developed metastases showed significant enrichment of EMT-related genes (GSEA NES 1.71, P = 0.025), oxidative phosphorylation, and immune-related pathways. EMT scores were consistently higher (more mesenchymal) in metastatic tumors across all scoring methods. Mesenchymal phenotype was associated with significantly worse overall survival (GSEA log-rank P = 0.0009).
conclusionsThis study demonstrates a correlation between mesenchymal gene expression signatures and increased metastatic risk in SS. EMT status, derived from primary tumor profiling at diagnosis, may serve as a potential prognostic biomarker. These findings support further investigation into EMT as a stratification tool for tailoring treatment intensity and surveillance strategies in SS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.